Geron (GERN)
(Delayed Data from NSDQ)
$4.29 USD
-0.33 (-7.14%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $4.28 -0.01 (-0.23%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Geron Corporation [GERN]
Reports for Purchase
Showing records 221 - 240 ( 243 total )
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
CASH BOLSTERED ? ESC TRIAL UNDERWAY ? ASSETS TO DRIVE VALUE IN 2011
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
3Q10 UPDATE - SPINAL CORD TRIAL UNDERWAY - IMETELSTAT IN PHASE 2
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
shers in the Era of hESC Therapy with First Patient Enrolled in Spinal Cord Trial
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Highlights from Meeting with Management - First Site Begins Screening for Spinal Cord Trial
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
2Q10 UPDATE PHASE 2 IMETELSTAT TRIAL STARTS - hESC TRIAL HOLD LIFTED
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
R&R?s Week in Review: Oncology and Stem Cell Sectors
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Initiates Phase 2 Program for Telomerase Inhibitor Imetelstat
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
1Q10 UPDATE - IMETELSTAT DATA AT AACR - SPINAL CORD TRIAL TO START 3Q10
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.